Last week’s significant research news included positive new Phase III data on Tezspire in nasal polyps from Amgen and ...

Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation ...

The prevalence of chronic sinusitis in China is about 8 percent, meaning it affects approximately 107 million people, ...

We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) ...

Amgen Inc. (NASDAQ:AMGN) 45th Annual TD Cowen Health Care Conference Transcript March 5, 2025 9:10 AM ETCompany ParticipantsJay Bradner - Executive ...

The Oklahoma Allergy and Asthma clinic is pushing back against proposed changes in coverage for asthma medications covered by ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Amgen's whale ...

Positive results from the Tezspire phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps: Cambridge, UK Tuesday, March 4, 2025, ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.